Dr Richard Bogle PhD FRCP FESC FACC DHMSA
Consultant Cardiologist
  • Home
  • NHS Practice
    • NHS Practice
    • St Helier Hospital
    • Epsom Cardiac Day Unit
    • St George's Hospital Radial Lounge
    • Echocardiography
  • Biography
    • Qualifications
    • About me >
      • Curriculum vitae
    • Appraisal and Revalidation
    • BCIS Angioplasty Audit
    • Publications
    • Recent abstracts
    • Research
    • Charitable activity
  • The Heart
    • Cardiac Investigations >
      • AliveCor ECG monitor
      • Guide to investigations for suspected angina
      • CT calcium scoring
      • Electrocardiogram (ECG)
      • Exercise treadmill test
      • Echocardiogram
      • Valve disease
      • Coronary Angiography
      • Pressure Wire Studies
      • Intra-vascular Ultrasound
    • Arrhythmias >
      • Atrial fibrillation >
        • Stroke Risk in AF
        • New Oral Anticoagulants
        • Presentations on AF
      • Atrial flutter
      • Pre-excitation syndromes
      • Ventricular ectopic beats
      • Ventricular arrhythmias
      • Pacemaker
      • DC Cardioversion
    • Cardiomyopathy
    • Coronary heart disease >
      • Cardiac syndrome X
      • Coronary Angioplasty
      • Coronary bypass surgery
    • Dizziness and blackouts
    • Fitness to fly
    • Fitness to drive
    • Heart Failure
    • Hypertension >
      • Patients guide to blood pressure medication
      • Home blood pressure monitors
      • Hypertension diet
      • Laragh's method
      • Renal sympathetic ablation for hypertension
      • Conn's Syndrome
    • Heart Screening >
      • Sports Cardiology
      • Cardiovascular Disease Risk
    • Medications >
      • Glyceryl trinitrate
    • Patient information leaflets
  • News and Links
  • Miscellany
    • History of Medicine
    • History of Coronary Angiography and Angioplasty
    • Stamps in Cardiology
    • A History of Medicine in 100 Objects
    • BSE Acceditation Course Introduction
    • BSE Acceditation Course Physics
    • BSE Acceditation Course Anatomy and Function
    • BSE Acceditation Course Mitral
    • BSE Acceditation Course Aortic
    • BSE Acceditation Course Congenital
    • BSE Acceditation Course Pericardium
  • Blog
  • RACPC Form
  • Cardiology Teaching St Helier Hospital

Are dialysis patients different?

10/1/2015

0 Comments

 
Picture
There is strong evidence that putting people with atrial fibrillation (AF) on warfarin reduces the risk of stroke by about two thirds. This is a big effect, consistently observed and has resulted in a large increase in prescription of warfarin and more recently non-warfarin based anticoagulants (NOACs). When deciding about anticoagulants use you constantly balance the expected reduction in stroke risk with the potential increased risk of bleeding. There are some patients, such as those on renal dialysis, who simply weren't included in the AF anticoagulant trials so it is reasonable to ask whether warfarin is equally effective and safe in these patients?

People on dialysis are regarded as a high risk group, often older, diabetic and have more vascular disease. They are at high risk of cardiovascular events. Atrial fibrillation is common and hence if you use the traditional scoring models (CHADS2 and CHADS2VASC) they are at high risk of stroke. Warfarin appears to be a reasonably safe drug for renal failure patients because it is not excreted by the kidney. So it would seem reasonable to treat a dialysis patient who goes into AF with warfarin and that is currently normal practice.

Last March a paper was published in Circulation which raised questions about the safely of this approach. This Canadian study used case-control methodology in people age 65 years or more admitted to hospital with AF. The patients were grouped into those on dialysis (haemodialysis or peritoneal dialysis) and non-dialysis patients and into those treated with warfarin or no-warfarin They researchers then determined the association between warfarin, stroke risk and bleeding in dialysis and non-dialysis patients.

There were 1626 dialysis patients and 204,210 nondialysis patients in the study. Of the dialysis patients 46% were prescribed warfarin and these people not surprisingly had more heart failure and diabetes. In patients on dialysis warfarin didn't reduced the risk of stroke but did increase the risk of bleeding by 44%. So these results are worrying and suggest the worst of both worlds: No benefit but with increased risk.

What of the non-dialysis patients in this study? Warfarin significantly reduced the stroke rate by 13% from 2.51 to 2.19% per year. Earlier in this article I wrote that warfarin reduces the risk of stroke in AF by 66%, which is much greater than that observed in the case controlled study. So there is something strange going on in this study because the expected benefit of warfarin in the non-dialysis patients wasn't seen either. whilst raising an interesting observation, at the moment this study is not strong enough evidence to stop using warfarin in renal dialysis patients.

There are a number of previous studies calling into question the efficacy of warfarin in dialysis patients and now with data potentially suggesting harm rather than just no benefit It must be time to conduct a randomised controlled trial of anticoagulation in patients with AF on dialysis. Since the data does not currently show benefit in this group it would be reasonable to design the trial to test anticoagulation versus a placebo. Funding for a trial of warfarin would be difficult but recently the FDA have approved Apixaban for used in patients with end stage renal failure on dialysis so this would be a great opportunity for a trial of this NOAC versus placebo to answer this question.

0 Comments

The man behind the protocol

1/1/2015

0 Comments

 
Picture
Before the Bruce protocol was used for exercise treadmill testing there was no standardised validated stress test for cardiac patients. Robert Bruce recognised that patient's were not reliably or reproducibly stressed by the techniques available and so developed a single and then a multistage exercise treadmill test in which individuals could attain a self-determined point of maximal exertion whilst having their blood pressure, heart rate and ECG monitored continuously. He testing the protocol in normal subjects and cardiac patients and showed the the feasibility, safety and clinical utility of the protocol which evolved into the modern seven-stage ‘Bruce protocol’ we know today. 

Each exercise stage lasts for 3 minutes, after which the treadmill speed and inclination increased. Bruce chose 3 min stages as this provided ‘the optimal compromise between requirements for physiological adaptations and minimal time for expeditious testing’. The protocol starts with a gentle, submaximal stress and gradually progresses to higher and higher workload.  The Bruce protocol exercise test is still used as the first-line investigation in patients with suspected coronary artery disease around the world although it has competition from newer non-invasive imaging technologies such as nuclear perfusion scanning and exercise echocardiography which have been shown to have better diagnostic accuracy.

Robert Bruce was born in 1916 and 7 years after graduation became the first chief of cardiology at the University of Washington School of Medicine in Seattle where he spent the rest of his career. His landmark 1963 paper first described the multistage protocol and despite his death 10 years ago his name lives on in the minds of generations of doctors as the ‘Bruce protocol’ treadmill test is used daily around the world.

0 Comments

    RSS Feed

    Picture

    Dr Richard Bogle

    The opinions expressed in this blog are strictly those of the author and should not be construed as the opinion or policy of my employers nor recommendations for your care or anyone else's. Always seek professional guidance instead.

    Archives

    November 2019
    March 2016
    February 2016
    May 2015
    April 2015
    March 2015
    February 2015
    January 2015
    December 2014
    November 2014
    October 2014
    September 2014
    August 2014
    July 2014
    June 2014
    May 2014
    April 2014
    March 2014
    February 2014
    January 2014
    November 2013
    October 2013
    August 2013
    July 2013
    June 2013
    May 2013
    April 2013
    March 2013
    February 2013
    January 2013

    Categories

    All
    Ablation
    Acute Coronary Syndromes
    Acute Coronary Syndromes
    Adherence
    Angioplasty
    Anticoagulants
    Arrhythmia
    Association
    Atherosclerosis
    Atrial Fibrillation
    Auenbrugger
    Bergamot
    Brugada
    Calcium Channel Blockers
    Cancer
    Cardiovascular Risk
    Chest Pain
    Cholesterol
    Cleveland Street
    Clinical Examination
    Colchicine
    Compliance
    Concordance
    Congenital Heart Disease
    Coronary Artery Disease
    Coronary Artery Disease
    C-reactive Protein
    Decision Aids
    Diet
    Ectopics
    Eggs
    Ezetimibe
    Frailty
    Frank's Sign
    Guidelines
    Hawthorne Effect
    Heart Failure
    History Of Medicine
    Hypertension
    ICD
    Internet
    Interventional Cardiology
    Joseph Rogers
    Lipids
    Malaria
    Marathon
    Medicines
    Nice Guidelines
    Nitrovasodilators
    NOAC
    Nudge
    Nutrition
    OCT
    Palpitations
    Pharmacy
    Pressure Wire
    Proteus
    Salt
    Smoking
    Spironolactone
    Statins
    Statistics
    Stent
    Stress
    Stroke
    Syndrome X
    Takotsubo
    Valve-disease
    Vein Grafts
    Ventricular Ectopics
    VF/VT
    Warfarin
    Weekend Working
    Workhouse

    View my profile on LinkedIn
Return to home page

Privacy Statement
Disclaimer
© Dr Richard Bogle 2020
patient feedback
Photo used under Creative Commons from peddhapati